US stock market anomaly | LB Pharmaceuticals (LBRX.US) debuts on the US stock market with an opening surge of over 20%

According to the Zhitong Financial APP, on Thursday, the biotechnology company LB Pharmaceuticals (LBRX.US), dedicated to developing drugs for neurological and psychiatric disorders, made its debut on the US stock market, with its opening stock price rising by over 20% to $18.12. The IPO price was $15. LB Pharmaceuticals' leading candidate drug, LB-102, is an oral small molecule drug preparing to enter Phase III clinical trials for the treatment of acute schizophrenia, a chronic disease characterized by hallucinations and delusions that affects approximately 1% of the US population. In a Phase II clinical trial involving 359 patients, the drug met its primary endpoint at week 4. LB Pharmaceuticals expects to begin Phase III clinical trials in the first quarter of 2026.